Free tool
FAERS Monitor: Levulan
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 020965 or its brand name (Levulan, Aminolevulinic Acid Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
1,433
Serious
182
13% of reports
Hospitalization
48
Death reported
9
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective244
- wrong technique in product usage process182
- poor quality product administered177
- product quality issue153
- product dose omission issue114
- erythema102
- accidental exposure to product79
- off label use78
- pain63
- product physical issue62
- blister48
- application site pain42
- application site erythema35
- product packaging quantity issue34
- skin exfoliation34
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2012 | 3 |
| 2013 | 6 |
| 2014 | 6 |
| 2015 | 13 |
| 2016 | 77 |
| 2017 | 64 |
| 2018 | 87 |
| 2019 | 77 |
| 2020 | 172 |
| 2021 | 66 |
| 2022 | 115 |
| 2023 | 167 |
| 2024 | 212 |
| 2025 | 235 |
| 2026 | 133 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,726 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| poor quality product administeredSignal | 177 | 250.7 | 218.1 | 43,056 |
| product physical issueSignal | 62 | 45.2 | 35.5 | 2,633 |
| product packaging quantity issueSignal | 34 | 44.3 | 31.8 | 1,392 |
| application site painSignal | 42 | 28.0 | 20.8 | 1,067 |
| application site erythemaSignal | 35 | 19.6 | 14.1 | 600 |
| product quality issueSignal | 153 | 16.6 | 14.2 | 2,232 |
| wrong technique in product usage processSignal | 182 | 13.2 | 11.5 | 2,057 |
| blisterSignal | 48 | 12.6 | 9.5 | 500 |
| accidental exposure to productSignal | 79 | 11.3 | 9.1 | 731 |
| erythemaSignal | 102 | 7.3 | 6.0 | 552 |
| skin exfoliationSignal | 34 | 5.9 | 4.2 | 135 |
| product dose omission issueSignal | 114 | 5.7 | 4.8 | 442 |
| drug ineffectiveSignal | 244 | 2.7 | 2.4 | 281 |
| pain | 63 | 1.5 | 1.2 | 10 |
| off label use | 78 | 1.3 | 1.1 | 6 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.